Form 4: Oncology Institute CFO Reports Acquisition of Shares

Robert Ross Carter, CFO of Oncology Institute, reports the acquisition of 197,368 shares of Class A Common Stock.

Summary

• Robert Ross Carter, the Chief Financial Officer of Oncology Institute, Inc. (TOI), filed a Form 4 with the SEC.
• The filing reports a transaction on March 31, 2025, where Carter acquired 197,368 shares of Class A Common Stock at $0.
• Following the transaction, Carter directly owns 236,775 shares of Class A Common Stock.
• The acquisition is related to RSU (Restricted Stock Unit) awards that vest over four years, subject to continued service with the company.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document is a standard SEC filing reporting an insider transaction. The acquisition of shares by the CFO is a positive sign, but it's part of a pre-determined compensation plan.

Positives

• The acquisition of shares by the CFO could be interpreted positively as it demonstrates confidence in the company's future.

Future Outlook

The vesting schedule of the RSUs suggests a commitment from the CFO to remain with the company for the next four years.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock.

Key Dates

Keywords

Form 4, Oncology Institute, TOI, Robert Ross Carter, CFO, Class A Common Stock, RSU, SEC